m(6)A-modified circFOXK2 in OSCC through the m(6)A-dependent IGF2BP3/GLUT1 axis, indicating a potential therapeutic target for OSCC.
m(6)A-modified circFOXK2 targets GLUT1 to accelerate oral squamous cell carcinoma aerobic glycolysis.